bedaquiline

bedaquiline

Interactive Data Dashboards

Track the HIV & TB response

Key indicators, province breakdowns and downloadable graphs.

  • Can you get TB care in the private sector? It is complicated

    In South Africa, tuberculosis is mainly diagnosed and treated in the public healthcare system. On paper, the private sector should also be able to deal with it, but in reality, TB care in this sector is often fragmented and confusing. Elri Voigt asks local experts why things work like this and what can be done…

    ·

  • Large numbers of TB survivors in SA struggling with lung damage, experts say

    There are over three million people alive in South Africa who have been cured of TB. But even after being cured, many continue to suffer the long-term after-effects of the disease. To find out more about this under-recognised problem, Spotlight recently attended a global gathering of experts focused on life after TB.

    ·

  • Pretoria company aims to lead SA in making key TB drug ingredients

    Though several South African companies are producing HIV and TB medicines, the active ingredients that go into these medicines are usually imported from India or China. Now, a local company is planning to break new ground by making the active ingredients for two important TB medicines in Pretoria. Catherine Tomlinson zooms in on the company’s…

    ·

  • Why the Competition Commission’s decision on two cancer medicine cases could have much wider implications

    There is a history of competition law being used to drive HIV medicine prices lower in South Africa. Now, two cases involving cancer medicines seem set to nail down what qualifies as “excessive pricing” in South African law – a legal development that could have far reaching implications for medicines prices in the country. Catherine…

    ·

  • Competition law has again worked to fight a bad drug patent, but we need other solutions

    A Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South Africa. Twenty years ago, a similar Competition Commission case resulted in a settlement that helped drive down the prices of several antiretrovirals, thereby helping to set the stage for the country’s HIV treatment programme. Fatima Hassan and…

    ·

  • Health in 2023 | A deceptively busy year in fewer than 1 000 words

    2023 was a busy year for healthcare in South Africa. We saw several promising policy developments, landmark court cases, important pieces of legislation, and some changes in leadership. Yet, take a step back and at facility level little seems to have changed. Shortages of healthcare workers persist, corruption is still rife, budgets tight, and our…

    ·

  • What next after shortened TB treatment fails in key trial?

    The current treatment for drug-susceptible tuberculosis (TB) used in South Africa last for six months, effectively cures TB and is dirt cheap. Two studies in recent years have shown that TB can be cured in four or in some cases even two months, but price and other complications make these treatments tricky to implement. At…

    ·

  • New resistance tests set to improve TB treatment

    Tuberculosis (TB) can be resistant to treatment with several different drugs. Tests that identify which drugs someone’s TB is resistant to are critical to ensuring that people are not treated with drugs that don’t work for them, especially given the significant side effects associated with some of the drugs. Elri Voigt assesses the state of…

    ·

  • TB treatment can be cut to two months for some, finds landmark study

    Some cases of tuberculosis (TB) can be successfully treated in as little as two months – a third of the current standard of six months. This is according to early findings from the landmark TRUNCATE TB trial presented at last week’s Union World Conference on Lung Health. Elri Voigt reports.

    ·

  • Francesca Conradie – from HIV to groundbreaking TB research

    Dr Francesca Conradie knew she wanted to be a doctor when she was eight years old. Now, 50 years later, she is a pioneer in the field of tuberculosis (TB) and led a landmark trial that changed how drug-resistant TB is treated. Aisha Abdool Karim spoke to her about the reasons behind her switch from…

    ·

  • Shorter, simpler DR-TB regimen expected later this year

    A new six-month treatment regimen for drug-resistant forms of tuberculosis is expected to be rolled out in the public sector later this year – current regimens take anything from nine to 18 months. Catherine Tomlinson unpacks why the switch is important and outlines what still needs to happen to make it a reality.

    ·

  • Are long-acting injections the future of TB prevention?

    Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.

    ·